Comparing PetVivo (PETV) and The Competition

PetVivo (NASDAQ:PETV) is one of 213 public companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its rivals? We will compare PetVivo to similar companies based on the strength of its earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability and risk.

Insider and Institutional Ownership

13.4% of PetVivo shares are held by institutional investors. Comparatively, 45.3% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 24.9% of PetVivo shares are held by insiders. Comparatively, 14.4% of shares of all “Surgical & medical instruments” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

PetVivo has a beta of 1.99, meaning that its share price is 99% more volatile than the S&P 500. Comparatively, PetVivo’s rivals have a beta of 1.30, meaning that their average share price is 30% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for PetVivo and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PetVivo	0	0	0	0	N/A
PetVivo Competitors	1063	3406	7377	194	2.56

As a group, “Surgical & medical instruments” companies have a potential upside of 36.84%. Given PetVivo’s rivals higher possible upside, analysts plainly believe PetVivo has less favorable growth aspects than its rivals.

Valuation & Earnings

This table compares PetVivo and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
PetVivo	$920,000.00	-$8.72 million	-2.19
PetVivo Competitors	$1.10 billion	$50.49 million	15.60

PetVivo’s rivals have higher revenue and earnings than PetVivo. PetVivo is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares PetVivo and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PetVivo	-988.42%	-863.27%	-317.41%
PetVivo Competitors	-648.50%	-318.18%	-30.61%

Summary

PetVivo rivals beat PetVivo on 8 of the 10 factors compared.

PetVivo Company Profile

PetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.